Gábor Rubovszky

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine · 2019 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Fabrice André, Eva Ciruelos, Dejan Juric et al. · Annals of Oncology · 2020 · 599 citations · Full text

Medicine, Oncology, Pharmacology +17

Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer

Ákos Sávolt, Gábor Péley, Csaba Polgár et al. · European Journal of Surgical Oncology · 2017 · 326 citations

Medicine, Oncology, Surgery +17

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer, Amylou C. Dueck, Miguel Martín et al. · The Lancet Oncology · 2021 · 255 citations

Medicine, Oncology, Pharmacology +15